UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~December~~March 2227, ~~2016~~2017

Interleukin Genetics, Inc.

(Exact Name of Registrant as Specified in ~~Its~~ Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-32715		94-3123681
(Commission File Number)		(IRS Employer Identification No.)

135 Beaver Street Waltham, MA		02452
(Address of Principal Executive Offices)		(Zip Code)

(781) 398-0700

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

¨ITEM ~~Soliciting~~2.05 ~~material~~Costs ~~pursuant~~Associated towith ~~Rule~~Exit ~~14a-12~~or ~~under~~Disposal ~~the Exchange Act (17 CFR 240~~Activities.~~14a-12)~~

¨The ~~Pre-commencement~~information ~~communications~~set ~~pursuant~~forth tounder ~~Rule~~“Restructuring” and ~~14d~~“Forward-~~2(b)~~Looking ~~under~~Statements” ~~the~~set ~~Exchange~~forth ~~Act~~in ~~(17~~Item ~~CFR 240~~8.~~14d-~~01 is hereby incorporated by reference into this Item 2~~(b))~~.05.

¨ITEM ~~Pre-commencement~~8.01 ~~communications~~Other ~~pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))~~Events

~~ITEM 1.01 Entry into a Material Definitive Agreement.~~Restructuring

~~The~~On ~~disclosure~~March ~~set~~27, ~~forth~~2017, ~~below~~the ~~under~~Board ~~Item~~of Directors 5of Interleukin Genetics, Inc.02 (bthe “Company”) approved a work force restructuring, which became effective and was completed on March 30, 2017, to better utilize the Company’s resources, to align the Company’s organization to support its emerging cardiovascular testing program, for which it is ~~incorporated~~seeking ~~herein~~strategic interest, and to streamline its commercial strategy for its ILUSTRA™ Inflammation Management Program. As a consequence of the restructuring, the Company reduced its workforce in its commercial organization and administrative functions by ~~reference~~eight persons. The Company will continue to support ILUSTRA program deployments with customers and will advance new customer relationships that expand the evidence base of its program effectiveness. As a result of the restructuring, the Company expects to incur aggregate expenses of approximately $58,000, consisting of (i) approximately $34,000 in cash severance payments and (ii) approximately $24,000 in accrued vacation payments. The Company expects that the restructuring will result in approximately $948,000 in reduced annualized operating expenses when fully implemented.

~~ITEM~~Delayed ~~5.02~~Filing ~~Departure~~ of ~~Directors~~Annual orReport ~~Certain~~on ~~Officers;~~Form ~~Election~~10-K offor ~~Directors;~~the ~~Appointment~~year ended ofDecember ~~Certain~~31, ~~Officers; Compensatory Arrangements of Certain Officers.~~2016

~~(b) On December~~The ~~22,~~Company ~~2016,~~also ~~Roger~~expects C.to ~~Colman,~~file awith the ~~director~~Securities ofand ~~Interleukin~~Exchange ~~Genetics,~~Commission ~~Inc.~~ (the “~~Company~~SEC”), ~~informed the Company that he was resigning as~~ a ~~director~~Form ~~effective~~12b-25 asNotification of ~~the~~Late ~~close~~Filing ofrelating ~~business~~to onits Annual ~~December~~Report ~~30,~~on ~~2016.~~Form ~~Pursuant~~10-K tofor the ~~terms~~year ofended ~~the~~December ~~Securities Purchase Agreement~~31, ~~dated July 29,~~ 2016, ~~by and among the Company and the investors identified on Schedule I thereto~~ (the “~~Agreement~~Form 10-K”), ~~Mr.~~ ~~Colman served~~ as ait ~~director~~is ~~designated~~unable byto ~~Pyxis~~file ~~Innovations, Inc. (“Pyxis”). Mr. Colman informed~~ the ~~Company that~~ heForm ~~was~~10-K ~~retiring~~by ~~from~~its ~~Pyxis~~March ~~and was also resigning as a director of the Company. Under the terms of the Agreement~~31, ~~Pyxis~~2017 ~~has~~due ~~the right to appoint a successor to replace Mr~~date. ~~Colman~~Pursuant ~~as its designee~~ to ~~the~~SEC ~~Board. Pyxis has~~regulations, ~~however, irrevocably waived its right under~~ the ~~Agreement~~Company towill ~~designate~~have ~~this~~until ~~representative~~April to17, be2017 ~~nominated for election~~ to ~~the Board and to replace any such designated~~timely ~~Board~~file ~~member~~its inForm ~~the event such Board member ceases to serve as a director for any reason~~10-K. ~~Pyxis retains the right under the Agreement to appoint one other board member (currently Joseph Landstra).~~

Forward-Looking Statements

Any statements in this Form 8-K about the Company’s future expectations, plans and prospects, including statements about its strategy, future operations, financial obligations, expected impact of the restructuring, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequently filed Quarterly Report on Form 10-Q. Any forward-looking statements contained in this Form 8-K speak only as of the date hereof and not of any future date, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTERLEUKIN GENETICS, INC.
Date: December 23, 2016	/s/ Mark B. Carbeau
Date: March 31, 2017	/s/ Mark B. Carbeau
	Mark B. Carbeau
	Chief Executive Officer

Filing Compare · INTERLEUKIN GENETICS INC